{
  "analysis_timestamp": "2026-01-09T03:11:35.296035",
  "analyses": {
    "benefit_factor": {
      "benefit_sub_factor": "Approved Use (USFDA only)",
      "weight": 50,
      "score": 3,
      "weighted_score": 150,
      "cdsco_approved": false,
      "usfda_approved": true
    },
    "market_experience": {
      "experience_sub_factor": "Established indication (>5Y, approved widely)",
      "weight": 90,
      "score": 5,
      "weighted_score": 450,
      "years_in_market": 65
    },
    "pubmed_evidence": {
      "evidence_sub_factor": "Low evidence (limited data, uncertain)",
      "weight": 30,
      "score": 1,
      "weighted_score": 30,
      "rct_count": 1
    },
    "raw_data": {
      "drug": "Spironolactone",
      "diagnosis": "Chronic Liver Disease",
      "patient_info": {
        "age": 60,
        "gender": "Male",
        "diagnosis": "Hyperlipidemia, Chronic Liver Disease",
        "condition": "decompensated cirrhosis",
        "allergies": [],
        "date_of_assessment": "2026-01-06"
      },
      "regulatory": {
        "drug": "Spironolactone",
        "condition": "Chronic Liver Disease",
        "cdsco_approved": false,
        "usfda_approved": true,
        "output": "Spironolactone is approved for use in Chronic Liver Disease as per USFDA's USPI (United States Prescriber information) but not as per the CDSCO (Indian health regulatory body)."
      },
      "market_experience": {
        "found": true,
        "generic_name": "SPIRONOLACTONE, SPIRONOLACTONE, SPIRONOLACTONE",
        "approval_date": "21-Jan-1960",
        "years": 65,
        "output": "SPIRONOLACTONE, SPIRONOLACTONE, SPIRONOLACTONE is first approved by USFDA on 21-Jan-1960 and first approved by CDSCO on [CDSCO approval date not available]. SPIRONOLACTONE, SPIRONOLACTONE, SPIRONOLACTONE is in the market for more than 65 years of post-market experience."
      },
      "pubmed_evidence": {
        "rct_count": 1,
        "top_conclusions": [
          {
            "title": "Improved bioavailability and clinical response in patients with chronic liver disease following the administration of a spironolactone: beta-cyclodextrin complex.",
            "conclusion": "Better absorption of spironolactone from the spironolactone: beta-cyclodextrin complex formulation should lead to a reduction in dosage and perhaps a more consistent effect in patients with chronic liver disease."
          }
        ]
      }
    }
  }
}